To access this element change to forms mode OFF
Grant Award View - GA171271
A randomized phase III study of neoadjuvant chemotherapy followed by...
GA ID:
GA171271
Agency:
Department of Health and Aged Care
Approval Date:
17-Apr-2021
Publish Date:
15-Jun-2021
Category:
Health and Medical Research
Grant Term:
1-Jun-2021 to 31-May-2026
Value (AUD):
$901,695.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 20/21 1.1 Health Policy Research and Analysis
Grant Program:
2020_MRFF_RCRDUN_RCRDUN_2021_General
Grant Activity:
A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Purpose:
Retroperitoneal sarcomas (RPS) are a diverse group of cancers that arise at the back of the abdominal cavity. The STRASS 2 study is designed to find out if a course of chemotherapy prior to surgery for RPS will reduce the risk of cancer recurrence and increase cure rates after surgery. It is the 1st study to look specifically at only 2 sarcoma types with the highest risk of cancer spreading. It also uses different chemotherapy drugs for each sarcoma type to ensure the best chance of response.
GO ID:
GO Title:
MRFF Clinical Trials Activity Initiative – 2020 Rare Cancers, Rare Diseases and Unmet Need General Grant Opportunity
Internal Reference ID:
MRF2006605
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, QLD
Postcode:
Multiple
Country:
AUSTRALIA